Select Language

KRAS

KRAS Overview

English Name	GTPase KRas	Approved Drugs	0
Drugs in Clinical Trials	40	Target Synonym	V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog，KRAS Proto-Oncogene， GTPase，K-Ras4B，KRAS1，KRAS2，V-Ki-Ras2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog，Kirsten Rat Sarcoma Viral Oncogene Homolog，GTPase KRas，C-Ki-Ras，K-Ras 2，RASK2，Kirsten Rat Sarcoma Viral Proto-Oncogene，Cellular Transforming Proto-Oncogene，Cellular C-Ki-Ras2 Proto-Oncogene，Kras-Enoph1 Fusion Protein，Transforming Protein P21，PR310 C-K-Ras Oncogene，C-Kirsten-Ras Protein，Proto-Oncogene GTPase，K-Ras P21 Protein，KRAS-ENOPH Fusion，Oncogene KRAS2，EC 3.6.5.2，C-Ki-Ras2，'C-K-RAS，C-K-RAS，K-RAS2A，K-RAS2B，K-RAS4A，C-K-Ras，KI-RAS，Ki-Ras，K-Ras，CFC2，RALD，NS3，OES，NS
Highest Development Stage	Phase 2 Clinical

English Name	GTPase KRas
Target Synonym	V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog，KRAS Proto-Oncogene， GTPase，K-Ras4B，KRAS1，KRAS2，V-Ki-Ras2 Kirsten Rat Sarcoma 2 Viral Oncogene Homolog，Kirsten Rat Sarcoma Viral Oncogene Homolog，GTPase KRas，C-Ki-Ras，K-Ras 2，RASK2，Kirsten Rat Sarcoma Viral Proto-Oncogene，Cellular Transforming Proto-Oncogene，Cellular C-Ki-Ras2 Proto-Oncogene，Kras-Enoph1 Fusion Protein，Transforming Protein P21，PR310 C-K-Ras Oncogene，C-Kirsten-Ras Protein，Proto-Oncogene GTPase，K-Ras P21 Protein，KRAS-ENOPH Fusion，Oncogene KRAS2，EC 3.6.5.2，C-Ki-Ras2，'C-K-RAS，C-K-RAS，K-RAS2A，K-RAS2B，K-RAS4A，C-K-Ras，KI-RAS，Ki-Ras，K-Ras，CFC2，RALD，NS3，OES，NS
Approved Drugs	0
Drugs in Clinical Trials	40
Highest Development Stage	Phase 2 Clinical

KRAS Product List

Product Category
Protein (13)
Product Status
Launched (13)
Species
Human (13)
Tag
His Tag (10)His Tag & Avi Tag (3)
Conjugate
Unconjugated (13)

Cat. No.	Species	Host	Product Description
HOT KRS-H5143	Human	E. coli	Human KRAS (G12V) Protein, His Tag (active enzyme)
HOT KRS-H51H3	Human	E. coli	Human KRAS (2-185, G12C) Protein, His Tag (active enzyme)
HOT KRS-H51H4	Human	E. coli	Human KRAS (2-185, G12D) Protein, His Tag (active enzyme)
HOT KRS-H51H6	Human	E. coli	Human KRAS Protein, His Tag (active enzyme, HPLC verified)
KRS-H5144	Human	E. coli	Human KRAS (G12S) Protein, His Tag (HPLC-verified) (active enzyme)
KRS-H51H1	Human	E. coli	Human KRAS (G12A) Protein, His Tag (active enzyme)
KRS-H51H2	Human	E. coli	Human KRAS (G12R) Protein, His Tag (active enzyme)
KRS-H51H5	Human	E. coli	Human KRAS (Q61H) Protein, His Tag (active enzyme)
KRS-H51H7	Human	E. coli	Human KRAS (G13D) Protein, His Tag (active enzyme)
KRS-H51Q3	Human	E. coli	Unconjugated Human KRAS (G12V) Protein, His,Avitag™ (active enzyme)

Total: 13

KRAS Background

KRAS (Kirsten rat sarcoma 2 viral oncogene homolog) gene is a proto-oncogene that encodes a small GTPase transductor protein called KRAS. KRAS is also known as Ki-Ras, c-K-ras and c-Ki-ras. Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. Plays an important role in the regulation of cell proliferation, promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a ZNF304-dependent manner. RAS is one of the most frequently mutated oncogenes in human cancer but the frequency and distribution of RAS gene mutations are not uniform. In details, mutation of glycine 12 (G12) causes RAS activation by interfering with GAP binding and GAP-stimulated GTP hydrolysis. The reference shows the pathway may as a potential therapy targets.

KRAS Synonyms

GTPase Kras,K-Ras 2,Ki-Ras,c-K-ras,c-Ki-ras,KRAS2,RASK2,C-K-RAS,CFC2,K-RAS2A,K-RAS2B,K-RAS4A,K-RAS4B,KI-RAS,KRAS1,KRAS2,NS,NS3,RASK2,KRAS

Clinical Drug Information

English Name	Research Code	Highest Development Stage	Company	Indication	Clinical Trial
Pooled mutant-KRAS peptide vaccine (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins)		Phase 2 Clinical	Sidney Kimmel Comprehensive Cancer Center	Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Pancreatic Neoplasms	Details
KRAS Neoantigen Nanovaccine (The Affiliated Nanjing Drum Tower Hospital Of Nanjing University Medical School)		Phase 2 Clinical	The Affiliated Nanjing Drum Tower Hospital Of Nanjing University Medical School	Colorectal Neoplasms; Pancreatic Neoplasms	Details
HBW-012462	HBW-012462	Phase 2 Clinical	Hyperway Pharmaceutical Co Ltd	Solid tumours	Details
JAB-23E73	JAB-23E73	Phase 2 Clinical	Jacobio Pharmaceuticals Group Co Ltd	Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Pancreatic Neoplasms; Solid tumours	Details
ZG-2001	ZG2001; ZG-2001	Phase 2 Clinical	Suzhou Zelgen Biopharmaceuticals Co Ltd	Neoplasms; Solid tumours	Details
ELI-002	ELI-002 2P; Amph-CpG-7909; ELI-002; VED-002	Phase 2 Clinical	Elicio Therapeutics	Bile Duct Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Cholangiocarcinoma; Colorectal Neoplasms; Gallbladder Neoplasms; Neoplasm, Residual; Ovarian Neoplasms; Solid tumours	Details
mDC3/8-KRAS Vaccine (University of Pennsylvania)		Phase 1 Clinical	University Of Pennsylvania	Carcinoma, Pancreatic Ductal	Details
small molecule Ras inhibitors (Boehringer Ingelheim/Vanderbilt University)		Phase 1 Clinical	Boehringer Ingelheim International Gmbh	Neoplasms	Details
KRAS peptide vaccine (Sidney Kimmel Cancer Center/Bristol-Myers Squibb)		Phase 1 Clinical	Sidney Kimmel Comprehensive Cancer Center	Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Pancreatic Neoplasms	Details
KrasG12D siRNA-loaded mesenchymal stromal cells-derived exosomes (Codiak BioSciences)		Phase 1 Clinical	The University Of Texas MD Anderson Cancer Center	Carcinoma, Pancreatic Ductal; Pancreatic Neoplasms	Details
HB-700	HB700; HB-700	Phase 1 Clinical	Hookipa Pharma Inc	Colorectal Neoplasms; Lung Neoplasms; Neoplasms; Pancreatic Neoplasms	Details
KST-6051	KST-6051	Phase 1 Clinical	Kestrel Therapeutics Inc	Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours	Details
TQB-3205	TQB-3205; TQB3205	Phase 1 Clinical	Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd	Neoplasms	Details
PT-0511	PT-0511; PT0511	Phase 1 Clinical	PAQ Therapeutics Inc	Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Pancreatic Neoplasms; Solid tumours	Details
TLN-372	TLN-372	Phase 1 Clinical	Treeline Biosciences Inc	Solid tumours	Details
ASP-5834	ASP5834; ASP-5834	Phase 1 Clinical	Astellas Pharma Inc	Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours	Details
AMG-410	AMG-410; AMG 410	Phase 1 Clinical	Amgen Inc	Colorectal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Pancreatic Neoplasms; Solid tumours	Details
MPD-1	MPD-1	Phase 1 Clinical	Pharosgen Co Ltd	Neoplasms; Solid tumours	Details
KRAS protein modulator (Eli Lilly and Company)		Phase 1 Clinical	Eli Lilly And Company	Neoplasms	Details
PF-07985045	PF-07985045; PF-5045	Phase 1 Clinical	Pfizer Inc	Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours	Details
LY-4066434	LY-4066434	Phase 1 Clinical	Loxo Oncology Inc	Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours	Details
BGB-53038	BGB-53038	Phase 1 Clinical	BeOne Medicines Ltd	Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Esophageal adenocarcinoma; Esophageal Neoplasms; Gastrointestinal Neoplasms; Lung Neoplasms; Neoplasm Metastasis; Solid tumours; Stomach Neoplasms	Details
KRAS Neoantigen mRNA Vaccine(Abogen Biosciences)	ABO2102; ABO-2102	Phase 1 Clinical	Abogen Biosciences Co Ltd	Carcinoma, Non-Small-Cell Lung; Pancreatic Neoplasms; Solid tumours	Details
PF-07934040	PF-4040; PF-07934040	Phase 1 Clinical	Pfizer Inc	Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Solid tumours	Details
ERAS-4001	ERAS-4001	Phase 1 Clinical	Erasca Inc	Solid tumours	Details
BBO-11818	BBO-11818	Phase 1 Clinical	Bridgebio Pharma Inc	Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms; Pancreatic Neoplasms	Details
ALTA-3263	ALTA-3263	Phase 1 Clinical	Alterome Therapeutics Inc	Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Neoplasms; Pancreatic Neoplasms; Solid tumours	Details
QTX-3544	QTX-3544; QTX3544	Phase 1 Clinical	Quanta Therapeutics Inc	Neoplasms; Solid tumours	Details
AN-9025	AN-9025; AN9025	Phase 1 Clinical	Hangzhou Adlai Nortye Biopharma Co Ltd	Adenocarcinoma of Lung; Colorectal Neoplasms; Neoplasm Metastasis; Neoplasms; Pancreatic Neoplasms; Solid tumours	Details
BI-3706674	BI-3706674; BI3706674; BI 3706674	Phase 1 Clinical	C.H. Boehringer Sohn Ag & Co. Kg	Esophageal Neoplasms; Solid tumours; Stomach Neoplasms	Details
YL-17231	YL-17231; YL17231; TEB-17231	Phase 1 Clinical	YL-Pharma	Neoplasms; Solid tumours	Details
QTX-3034	QTX3034; QTX-3034	Phase 1 Clinical	Quanta Therapeutics Inc	Neoplasms; Solid tumours	Details
Zoldonrasib	RMC-9805; RM-036	Phase 1 Clinical	Revolution Medicines Inc	Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Colorectal Neoplasms; Neoplasms; Solid tumours	Details
BEBT-607	C200825009-FP; BEBT-607	Phase 1 Clinical	Guangzhou BeBetter Medicine Technology Co	Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Solid tumours	Details
BI-1701963	BI-1701963	Phase 1 Clinical	Forma Therapeutics Holdings Inc	Colorectal Neoplasms; Solid tumours	Details
Targeted KRAS TCR-T cell therapy(Immuxell Biotech)		Clinical	Shanghai Immuxell Biotech Ltd	Carcinoma, Pancreatic Ductal	Details
CWG-59r	CWG-59r; CWG-59-r; CWG59r	Clinical	Cellworks Group	Neoplasms	Details
CWG-71b	CWG-71b; CWG-71-b; CWG71b	Clinical	Cellworks Group	Neoplasms	Details
CWG-89	CWG-89	Clinical	Cellworks Group	Neoplasms	Details
CWG-71a (Cellworks Group)	CWG-71a	Clinical	Cellworks Group Inc	Neoplasms	Details